Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Cytoxan	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
None	O
History	O
of	O
Present	O
Illness:	O
Ms.	O
___	O
is	O
a	O
___	O
woman	O
with	O
kappa	O
anaplastic	O
plasma	O
cell	O
myeloma	O
diagnosed	O
in	O
___	O
with	O
extensive	O
skull,	O
pelvic,	O
and	O
hip	O
involvement	O
as	O
well	O
as	O
trace	O
B-J	O
proteinuria,	O
30%	O
plasma	O
cell	O
involvement	O
and	O
unfavorable	O
cytogenetics	O
s/p	O
radiation	O
to	O
skull	O
and	O
iliac	O
masses,	O
and	O
Velcade/dex	O
with	O
significant	O
FLC	O
and	O
BM	O
response,	O
s/p	O
6	O
autoSCT	O
(___)	O
who	O
was	O
on	O
___	O
maintenance	O
but	O
has	O
a	O
recent	O
relapse	O
with	O
bony	O
disease	O
and	O
iliac	O
mass	O
now	O
presenting	O
for	O
Cytoxan	O
Past	O
Medical	O
History:	O
ONCOLOGIC	O
HISTORY:	O
Ms.	O
___	O
developed	O
sudden-onset	O
right	O
lateral	O
hip	O
pain	O
in	O
___.	O
She	O
had	O
a	O
similar	O
episode	O
___	O
years	O
prior	O
that	O
resolved	O
with	O
physical	O
therapy.	O
She	O
was	O
initially	O
diagnosed	O
with	O
bursitis	O
and	O
was	O
referred	O
to	O
physical	O
therapy,	O
with	O
which	O
her	O
pain	O
only	O
slightly	O
improved.	O
She	O
had	O
difficulty	O
walking	O
normally.	O
Plain	O
films	O
of	O
the	O
hips	O
on	O
___	O
showed	O
a	O
possible	O
lucent	O
lesion	O
within	O
the	O
right	O
iliac	O
bone.	O
Follow-up	O
MRI	O
reportedly	O
was	O
consistent	O
with	O
a	O
large	O
destructive	O
right	O
iliac	O
mass	O
with	O
soft	O
tissue	O
components,	O
additional	O
lesion	O
in	O
the	O
femoral	O
neck	O
shaft,	O
pelvis	O
and	O
sacrum.	O
She	O
was	O
evaluated	O
by	O
Dr.	O
___	O
on	O
___,	O
who	O
felt	O
the	O
imaging	O
was	O
most	O
consistent	O
with	O
multiple	O
myeloma	O
with	O
some	O
extra-skeletal	O
soft	O
tissue	O
component	O
versus	O
lymphoma.	O
She	O
underwent	O
CT	O
torso	O
on	O
___	O
(see	O
below)	O
followed	O
by	O
U/S-guided	O
biopsy	O
of	O
the	O
soft	O
tissue	O
mass	O
in	O
the	O
right	O
iliac	O
bone	O
on	O
___.	O
A	O
bone	O
scan	O
was	O
obtained	O
on	O
___.	O
This	O
showed	O
concerning	O
findings	O
in	O
the	O
skull,	O
for	O
which	O
the	O
patient	O
was	O
referred	O
to	O
the	O
ED	O
and	O
admitted.	O
While	O
she	O
was	O
hospitalized,	O
head	O
MRI	O
was	O
obtained	O
which	O
showed	O
numerous	O
calvarial	O
masses,	O
with	O
the	O
largest	O
invading	O
the	O
dura	O
and	O
compressing	O
the	O
occipital	O
lobe.	O
Neurosurgery	O
and	O
Neuro-Onc	O
(Dr.	O
___	O
were	O
consulted,	O
and	O
felt	O
that	O
she	O
was	O
safe	O
for	O
discharge	O
with	O
close	O
outpatient	O
follow-up.	O
Kappa	O
LCs	O
returned	O
significantly	O
elevated.	O
Immunoglobulins	O
were	O
all	O
reduced.	O
She	O
had	O
no	O
other	O
end-organ	O
dysfunction,	O
but	O
we	O
did	O
recommend	O
holding	O
NSAIDs	O
and	O
starting	O
opiates	O
instead	O
for	O
hip	O
pain	O
to	O
prevent	O
renal	O
dysfunction.	O
She	O
was	O
discharged	O
on	O
___.	O
In	O
the	O
meantime,	O
pathology	O
was	O
reviewed	O
and	O
confirmed	O
an	O
anaplastic	O
plasma	O
cell	O
myeloma.	O
She	O
was	O
readmitted	O
___	O
to	O
begin	O
C1	O
Velcade/dex	O
with	O
concurrent	O
radiation	O
of	O
her	O
head.	O
BM	O
biopsy	O
that	O
day	O
showed	O
a	O
subset	O
of	O
plasma	O
cells	O
with	O
anaplastic	O
features	O
comprising	O
30%	O
of	O
the	O
marrow	O
cellularity.	O
Hip	O
MRI	O
on	O
___	O
showed	O
diffuse	O
metastatic	O
disease	O
throughout	O
the	O
pelvic	O
bones	O
and	O
proximal	O
femurs	O
with	O
a	O
dominant	O
lesion	O
in	O
the	O
right	O
iliac	O
bone	O
extending	O
into	O
the	O
right	O
acetabulum	O
and	O
the	O
adjacent	O
soft	O
tissues;	O
overall,	O
these	O
lesions	O
appeared	O
unchanged	O
in	O
number	O
and	O
mildly	O
increased	O
in	O
size	O
from	O
the	O
___	O
exam;	O
the	O
degree	O
of	O
involvement	O
of	O
the	O
right	O
supra-acetabular	O
iliac	O
bone,	O
likely	O
poses	O
is	O
a	O
risk	O
for	O
pathologic	O
fracture	O
of	O
the	O
acetabular	O
roof.	O
Skeletal	O
survey	O
showed	O
extensive	O
disease	O
in	O
calvarium	O
and	O
R	O
pelvis.	O
Facial	O
CT	O
on	O
___	O
showed	O
a	O
large	O
lytic	O
lesion	O
in	O
the	O
body	O
of	O
the	O
right	O
mandible	O
with	O
erosion	O
into	O
the	O
adjacent	O
soft	O
tissue,	O
and	O
additional	O
lesions	O
involving	O
the	O
right	O
mandibular	O
condyle	O
and	O
ramus.	O
She	O
was	O
given	O
dex	O
___	O
mg	O
daily	O
x	O
4	O
days	O
and	O
Velcade	O
1.3	O
mg/m2	O
IV.	O
She	O
was	O
discharged	O
___.	O
Her	O
free	O
kappa	O
decreased	O
from	O
350.9	O
to	O
23.8	O
after	O
one	O
cycle	O
with	O
Velcade/dex	O
and	O
radiation	O
therapy.	O
She	O
completed	O
3500	O
cGy	O
radiation	O
on	O
___.	O
BM	O
biopsy	O
___	O
showed	O
30%	O
plasma	O
cells	O
and	O
complex	O
karyotype	O
including	O
gain	O
of	O
odd	O
number	O
chromosomes,	O
monosomy	O
13,	O
and	O
der(14)t(11;14).	O
At	O
least	O
two	O
related	O
neoplastic	O
clones	O
were	O
detected,	O
indicative	O
of	O
cytogenetic	O
evolution.	O
Concurrent	O
FISH	O
showed	O
monosomy	O
13	O
and	O
partial	O
deletion	O
of	O
IGH,	O
likely	O
resulted	O
from	O
der(14)t(11;14).	O
SUMMARY	O
OF	O
RADIATION	O
THERAPY:	O
___	O
TREATMENT	O
SITE:	O
Posterior	O
Skull.	O
TECHNIQUE	O
FIELD	O
/	O
SIZE	O
(CM):	O
2-field/	O
L	O
LAT,	O
11.6	O
x	O
14	O
cm;	O
___	O
95,	O
11.6	O
x	O
14	O
cm.	O
BEAM	O
ENERGY:	O
___	O
MV	O
DOSE	O
PER	O
FRACTION	O
(cGy):	O
250	O
NUMBER	O
OF	O
FRACTIONS:	O
14	O
TOTAL	O
TIME	O
(DAYS):	O
18	O
(inclusive)	O
DATES	O
FROM-TO:	O
___	O
to	O
___	O
TOTAL	O
DOSE	O
(cGy):	O
3500	O
TREATMENT	O
SITE:	O
Right	O
Hip.	O
TECHNIQUE	O
FIELD	O
/	O
SIZE	O
(CM):	O
APPA/	O
AP	O
180,	O
18.1	O
x	O
25.5	O
cm;	O
PA	O
0,	O
16.8	O
x	O
25	O
cm	O
BEAM	O
ENERGY:	O
___	O
MV	O
DOSE	O
PER	O
FRACTION	O
(cGy):	O
250	O
NUMBER	O
OF	O
FRACTIONS:	O
14	O
TOTAL	O
TIME	O
(DAYS):	O
18	O
(inclusive)	O
DATES	O
FROM-TO:	O
___	O
to	O
___	O
TOTAL	O
DOSE	O
(cGy):	O
3500	O
ONCOLOGIC	O
TREATMENT	O
HISTORY:	O
-C1	O
VD	O
+	O
RT	O
as	O
above	O
-___:	O
C2D1	O
CVD	O
+	O
Zometa	O
-___:	O
C3D1	O
CVD	O
-___:	O
C4D1	O
CVD	O
-___:	O
C5D1	O
CVD	O
-___:	O
C6D1	O
CVD	O
+	O
Zometa	O
-___:	O
CTX	O
1000	O
mg/m2	O
for	O
stem	O
cell	O
mobilization	O
We	O
performed	O
a	O
repeat	O
BM	O
biopsy	O
on	O
___	O
to	O
evaluate	O
response,	O
which	O
showed	O
<5%	O
plasma	O
cells	O
and	O
normal	O
karyotype	O
(unlike	O
previous	O
complex	O
karyotype).	O
-___:	O
D0	O
AutoSCT	O
with	O
melphalan	O
conditioning	O
(3	O
bags	O
infused	O
___	O
CD34/kg	O
=	O
5.11e6).	O
Post-transplant	O
course	O
was	O
complicated	O
by	O
febrile	O
neutropenia	O
(cultures	O
negative),	O
dysphagia,	O
nausea/vomiting/diarrhea.	O
She	O
subsequently	O
had	O
tachycardia	O
but	O
V/Q	O
scan	O
___	O
was	O
low-probability	O
for	O
PE.	O
TTE	O
___	O
was	O
normal	O
and	O
unchanged.	O
-___:	O
Slight	O
trend	O
upwards	O
in	O
free	O
kappa,	O
late	O
___	O
was	O
started	O
prior	O
to	O
d100	O
to	O
try	O
to	O
prevent	O
disease	O
progression.	O
-___:	O
Started	O
second	O
cycle	O
of	O
___	O
(21	O
days	O
on,	O
7	O
days	O
off),	O
slight	O
fatigue	O
-___:	O
Increasing	O
R	O
hip	O
pain	O
over	O
a	O
week,	O
plain	O
films	O
negative,	O
MRI	O
___	O
showed	O
recurrent	O
___	O
disease	O
at	O
previous	O
site	O
in	O
pelvis	O
and	O
L	O
femur	O
at	O
risk	O
for	O
fracture,	O
admitted	O
for	O
pain	O
control	O
and	O
to	O
initiate	O
XRT	O
and	O
velcade	O
dex	O
(___)	O
-___	O
Bone	O
marrow:	O
10%	O
kappa	O
restricted	O
plasma	O
cells	O
wtih	O
t(1;11)(p22;q12)	O
which	O
was	O
previously	O
reported	O
c/w	O
recurrence.	O
-___	O
velcade	O
dex	O
C1	O
-___	O
completed	O
XRT	O
to	O
L	O
femur/hip/sacrum	O
to	O
prevent	O
pathologic	O
fracture	O
-___	O
biopsy	O
of	O
R	O
gluteal	O
mass,	O
poorly	O
differentiated	O
neoplasm,	O
immunostains	O
pending	O
OTHER	O
PAST	O
MEDICAL	O
HISTORY:	O
-History	O
of	O
mild	O
osteoporosis,	O
has	O
been	O
on	O
bisphosphonate	O
for	O
___	O
years	O
and	O
stopped.	O
-Recurrent	O
right	O
breast	O
atypical	O
ductal	O
hyperplasia	O
in	O
___	O
and	O
in	O
___,	O
s/p	O
biopsies	O
by	O
Dr.	O
___.	O
Was	O
on	O
raloxifene	O
for	O
___	O
years	O
(___),	O
then	O
saw	O
Dr.	O
___	O
at	O
___	O
and	O
was	O
switched	O
to	O
alendronate	O
___,	O
stopped	O
1	O
month	O
ago).	O
Has	O
had	O
annual	O
mammograms	O
since	O
then,	O
no	O
further	O
abnormalities.	O
-Last	O
Pap	O
a	O
few	O
years	O
ago.	O
One	O
abnormal	O
Pap	O
decades	O
ago,	O
thinks	O
she	O
had	O
a	O
colposcopy	O
which	O
was	O
normal.	O
-Colonoscopy	O
___:	O
A	O
single	O
sessile	O
10	O
mm	O
polyp	O
of	O
benign	O
appearance	O
was	O
found	O
in	O
the	O
sigmoid	O
colon	O
at	O
30cm.	O
Path:	O
normal	O
mucosa.	O
PAST	O
SURGICAL	O
HISTORY:	O
-Excision	O
of	O
right	O
breast	O
ductal	O
hyperplasia	O
in	O
___	O
and	O
___.	O
-Excision	O
of	O
pilonidal	O
sinus.	O
-Right	O
clavicle	O
fracture	O
in	O
___.	O
Social	O
History:	O
___	O
Family	O
History:	O
___.	O
Maternal	O
aunt	O
had	O
breast	O
cancer	O
in	O
her	O
___,	O
no	O
known	O
genetic	O
testing.	O
Multiple	O
other	O
female	O
relatives	O
have	O
not	O
had	O
any	O
breast,	O
ovarian,	O
or	O
GI	O
malignancies.	O
No	O
known	O
hematologic	O
malignancies.	O
Physical	O
Exam:	O
ADMISSION	O
PHYSICAL	O
EXAM:	O
GEN:	O
NAD.	O
pale,	O
non-toxic.	O
Speaking	O
full	O
sentences	O
VS:	O
98.1	O
100/56	O
80	O
18	O
99%RA	O
PAIN:	O
___	O
LOCATION:	O
Right	O
hip	O
HEENT:	O
PERRL,	O
EOMI,	O
MMM,	O
clear	O
oropharynx,	O
no	O
mucositis,	O
good	O
dentition.	O
Posterior	O
skull	O
lesions	O
have	O
resolved	O
leaving	O
indentations.	O
L	O
frontal	O
bony	O
prominence	O
on	O
skull,	O
painful	O
to	O
palpation.	O
LYMPH:	O
No	O
supraclavicular,	O
axillary,	O
pre/post	O
auricular	O
LAD	O
CV:	O
S1,	O
S2,	O
RRR.	O
No	O
M/R/G	O
PULM:	O
Non-labored.	O
No	O
rales,	O
wheezing	O
or	O
rhonchi.	O
CTAB	O
ABD:	O
Soft,	O
NT,	O
ND,	O
BS+,	O
no	O
HSM.	O
EXT:	O
WWP.	O
No	O
edema	O
Skin:	O
No	O
rash,	O
new	O
bruising	O
or	O
breakdown	O
MSK:	O
Pain	O
with	O
palpation	O
on	O
R	O
iliac	O
crest,	O
and	O
pain	O
with	O
internal	O
and	O
external	O
rotation	O
(passive	O
or	O
active)	O
at	O
R	O
hip,	O
improved	O
since	O
yesterday.	O
Full	O
ROM	O
on	O
left	O
leg/hip.	O
Gait	O
is	O
antalgic.	O
Strength	O
is	O
___	O
hip	O
flexion	O
on	O
R	O
hip.	O
PSYCH:	O
Teary	O
and	O
sad	O
about	O
relapse	O
disease.	O
DISCHARGE	O
PHYSICAL	O
EXAM:	O
GEN:	O
NAD.	O
pale,	O
non-toxic.	O
Speaking	O
full	O
sentences	O
VS:	O
REFER	O
TO	O
FLOWSHEET	O
PAIN:	O
___	O
LOCATION:	O
Right	O
hip	O
HEENT:	O
PERRL,	O
EOMI,	O
MMM,	O
clear	O
oropharynx,	O
no	O
mucositis,	O
good	O
dentition.	O
Posterior	O
skull	O
lesions	O
have	O
resolved	O
leaving	O
indentations.	O
L	O
frontal	O
bony	O
prominence	O
on	O
skull,	O
painful	O
to	O
palpation.	O
LYMPH:	O
No	O
supraclavicular,	O
axillary,	O
pre/post	O
auricular	O
LAD	O
CV:	O
S1,	O
S2,	O
RRR.	O
No	O
M/R/G	O
PULM:	O
Non-labored.	O
No	O
rales,	O
wheezing	O
or	O
rhonchi.	O
CTAB	O
ABD:	O
Soft,	O
NT,	O
ND,	O
BS+,	O
no	O
HSM.	O
EXT:	O
WWP.	O
No	O
edema	O
Skin:	O
No	O
rash,	O
new	O
bruising	O
or	O
breakdown	O
MSK:	O
Pain	O
with	O
palpation	O
on	O
R	O
iliac	O
crest,	O
and	O
pain	O
with	O
internal	O
and	O
external	O
rotation	O
(passive	O
or	O
active)	O
at	O
R	O
hip,	O
improved.	O
Full	O
ROM	O
on	O
left	O
leg/hip.	O
Gait	O
is	O
antalgic.	O
Strength	O
is	O
___	O
hip	O
flexion	O
on	O
R	O
hip.	O
PSYCH:	O
Teary	O
and	O
sad	O
about	O
relapse	O
disease.	O
Pertinent	O
Results:	O
LABS:	O
___	O
07:20AM	O
BLOOD	O
WBC-2.5*	O
RBC-2.92*	O
Hgb-8.9*	O
Hct-27.1*	O
MCV-93	O
MCH-30.5	O
MCHC-32.8	O
RDW-18.6*	O
RDWSD-61.7*	O
Plt	O
Ct-74*	O
___	O
09:55AM	O
BLOOD	O
WBC-4.8#	O
RBC-3.13*	O
Hgb-9.5*	O
Hct-29.7*	O
MCV-95	O
MCH-30.4	O
MCHC-32.0	O
RDW-17.0*	O
RDWSD-57.8*	O
Plt	O
___	O
___	O
07:20AM	O
BLOOD	O
Neuts-80*	O
Bands-0	O
Lymphs-5*	O
Monos-11	O
Eos-2	O
Baso-0	O
Atyps-2*	O
___	O
Myelos-0	O
AbsNeut-2.00	O
AbsLymp-0.18*	O
AbsMono-0.28	O
AbsEos-0.05	O
AbsBaso-0.00*	O
___	O
09:55AM	O
BLOOD	O
Neuts-80*	O
Bands-0	O
Lymphs-7*	O
Monos-11	O
Eos-2	O
Baso-0	O
___	O
Myelos-0	O
AbsNeut-3.84	O
AbsLymp-0.34*	O
AbsMono-0.53	O
AbsEos-0.10	O
AbsBaso-0.00*	O
___	O
07:20AM	O
BLOOD	O
Hypochr-NORMAL	O
Anisocy-1+	O
Poiklo-NORMAL	O
Macrocy-1+	O
Microcy-NORMAL	O
Polychr-NORMAL	O
___	O
09:55AM	O
BLOOD	O
Hypochr-NORMAL	O
Anisocy-NORMAL	O
Poiklo-NORMAL	O
Macrocy-NORMAL	O
Microcy-NORMAL	O
Polychr-NORMAL	O
___	O
07:20AM	O
BLOOD	O
Plt	O
Smr-VERY	O
LOW	O
Plt	O
Ct-74*	O
___	O
09:55AM	O
BLOOD	O
Plt	O
Smr-LOW	O
Plt	O
___	O
___	O
07:20AM	O
BLOOD	O
Glucose-106*	O
UreaN-11	O
Creat-0.3*	O
Na-139	O
K-3.7	O
Cl-110*	O
HCO3-25	O
AnGap-8	O
___	O
09:55AM	O
BLOOD	O
UreaN-17	O
Creat-0.4	O
Na-136	O
K-3.3	O
Cl-102	O
HCO3-25	O
AnGap-12	O
___	O
07:20AM	O
BLOOD	O
ALT-52*	O
AST-23	O
LD(LDH)-361*	O
AlkPhos-229*	O
TotBili-0.2	O
___	O
09:55AM	O
BLOOD	O
ALT-43*	O
AST-28	O
AlkPhos-214*	O
TotBili-0.2	O
___	O
07:20AM	O
BLOOD	O
Albumin-2.6*	O
Calcium-7.6*	O
Phos-1.5*	O
Mg-2.5	O
UricAcd-2.5	O
___	O
09:55AM	O
BLOOD	O
TotProt-5.3*	O
Albumin-3.2*	O
Globuln-2.1	O
Calcium-8.6	O
Phos-2.5*	O
Mg-2.1	O
___	O
09:55AM	O
BLOOD	O
PEP-PND	O
___	O
Fr	O
K/L-0.89	O
IgG-333*	O
IgA-68*	O
IgM-13*	O
IMAGING:	O
MRI	O
PELVIS	O
___	O
IMPRESSION:	O
No	O
significant	O
interval	O
change	O
compared	O
to	O
most	O
recent	O
prior	O
study	O
with	O
multiple	O
enhancing	O
lesions	O
seen	O
from	O
the	O
pelvis,	O
the	O
largest	O
within	O
the	O
right	O
iliac	O
bone	O
and	O
acetabulum	O
which	O
demonstrates	O
complete	O
replacement	O
of	O
the	O
marrow	O
with	O
lesion,	O
post	O
treatment	O
changes,	O
and	O
a	O
large	O
soft	O
tissue	O
component	O
with	O
extensive	O
peritumoral	O
edema.	O
There	O
is	O
no	O
evidence	O
of	O
pathologic	O
fracture.	O
Slight	O
increase	O
in	O
the	O
right	O
hip	O
effusion	O
Brief	O
Hospital	O
Course:	O
ASSESSMENT/PLAN:	O
___	O
woman	O
with	O
kappa	O
anaplastic	O
plasma	O
cell	O
myeloma	O
diagnosed	O
in	O
___	O
with	O
extensive	O
skull,	O
pelvic,	O
and	O
hip	O
involvement	O
as	O
well	O
as	O
trace	O
B-J	O
proteinuria,	O
30%	O
plasma	O
cell	O
involvement	O
and	O
unfavorable	O
cytogenetics,	O
s/p	O
radiation	O
to	O
skull	O
and	O
iliac	O
masses,	O
and	O
Velcade/dex	O
with	O
significant	O
FLC	O
and	O
BM	O
response,	O
s/p	O
autoSCT	O
(___)	O
who	O
was	O
on	O
maintenance	O
lenalidomide,	O
found	O
to	O
have	O
recent	O
relapse	O
with	O
bone	O
disease	O
and	O
R	O
gluteal	O
mass,	O
now	O
s/p	O
one	O
cycle	O
velcade/dex	O
and	O
recently	O
completed	O
XRT	O
to	O
the	O
L	O
femur/pelvis	O
here	O
for	O
Cytoxan.	O
#Anaplastic	O
plasma	O
cell	O
myeloma	O
s/p	O
autoSCT:	O
D0	O
___	O
with	O
recent	O
relapse	O
of	O
disease	O
as	O
noted	O
above.	O
-Bortezomib	O
2	O
mg	O
SC	O
Days	O
1,	O
4,	O
8	O
and	O
___,	O
___	O
and	O
___	O
mg/m2)	O
-Dexamethasone	O
20	O
mg	O
PO	O
D1,	O
4,	O
8,	O
11	O
with	O
bortezomib.	O
Will	O
also	O
receive	O
on	O
D2	O
and	O
D3	O
per	O
protocol	O
-Cyclophosphamide	O
1500	O
mg	O
IV	O
Day	O
1.	O
___	O
mg/m2)	O
-Antiemetics	O
and	O
hydration	O
per	O
protocol	O
-UA	O
stable,	O
w/o	O
hematuria	O
-Continue	O
infectious	O
prophy	O
-MR	O
___	O
w/o	O
evidence	O
of	O
pathologic	O
fracture	O
but	O
no	O
significant	O
interval	O
change	O
compared	O
to	O
the	O
most	O
recent	O
study	O
-Plan	O
to	O
follow	O
up	O
outpatient	O
___	O
for	O
XRT	O
and	O
further	O
management	O
of	O
care	O
#Pain:	O
On	O
Oxycodone	O
5mg	O
q4hrs	O
PRN	O
for	O
breakthrough	O
and	O
Oxycontin	O
10mg	O
Q8hrs.	O
However,	O
increased	O
oxycontin	O
to	O
20mg	O
TID	O
___	O
to	O
better	O
control	O
pain.	O
Patient	O
was	O
unable	O
to	O
tolerate	O
XRT	O
due	O
to	O
pain	O
prior	O
to	O
admission.	O
The	O
plan	O
is	O
to	O
continue	O
with	O
XRT	O
in	O
hopes	O
that	O
it	O
will	O
help	O
control	O
her	O
pain	O
better	O
in	O
addition	O
to	O
the	O
therapy	O
she	O
is	O
receiving.	O
#Anemia:	O
Likely	O
due	O
to	O
hemodilution,	O
received	O
500ml	O
NS	O
bolus	O
prior	O
to	O
admission	O
in	O
addition	O
to	O
NS	O
boluses	O
pre	O
and	O
post	O
cytoxan	O
with	O
maintenance	O
hydration.	O
Transfuse	O
if	O
Hgb	O
<	O
7	O
and/or	O
symptomatic.	O
Received	O
1	O
unit	O
prbcs	O
___	O
as	O
hgb	O
trending	O
down.	O
#Nutrition.	O
Low	B-Malnutrition
albumin	B-Malnutrition
and	O
phos,	O
slightly	O
tachycardic	O
on	O
admission	O
and	O
has	O
not	O
been	O
eating/drinking	O
well	O
at	O
home.	O
Repleting	B-Malnutrition
lytes	B-Malnutrition
PRN.	O
Ensure	O
TID	O
with	O
meals	O
while	O
in	O
house	O
and	O
continue	O
at	O
home.	O
Received	O
500cc	O
bolus	O
of	O
NS	O
in	O
clinic	O
prior	O
to	O
admission.	O
#Mood:	O
Anxious,	O
depressed	O
due	O
to	O
relapse	O
in	O
disease.	O
Continues	O
to	O
be	O
very	O
tearful	O
and	O
emotional.	O
This	O
is	O
contributing	O
to	O
low	O
appetite	O
and	O
a	O
6lb	O
weight	O
loss	O
in	O
last	O
few	O
months.	O
Initiated	O
mirtazapine	O
on	O
admission.	O
Monitoring	O
closely	O
for	O
serotonin	O
syndrome	O
#Infectious	O
prophylaxis:	O
-	O
PCP:	O
___	O
-	O
HSV/VZV:	O
Acyclovir	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Acyclovir	O
400	O
mg	O
PO	O
Q8H	O
2.	O
Lidocaine-Prilocaine	O
1	O
Appl	O
TP	O
ONCE	O
3.	O
Lorazepam	O
0.5-1	O
mg	O
PO	O
TID	O
PRN	O
anxiety	O
prior	O
to	O
IV	O
placement	O
4.	O
Mirtazapine	O
7.5	O
mg	O
PO	O
QHS	O
5.	O
Omeprazole	O
20	O
mg	O
PO	O
DAILY	O
6.	O
OxycoDONE	O
(Immediate	O
Release)	O
5	O
mg	O
PO	O
Q4H:PRN	O
pain	O
7.	O
OxyCODONE	O
SR	O
(OxyconTIN)	O
10	O
mg	O
PO	O
Q8H	O
8.	O
Sulfameth/Trimethoprim	O
SS	O
1	O
TAB	O
PO	O
DAILY	O
9.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
10.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
11.	O
Ibuprofen	O
200	O
mg	O
PO	O
Q6H:PRN	O
pain	O
12.	O
FoLIC	O
Acid	O
0.8	O
mg	O
PO	O
DAILY	O
13.	O
Vitamin	O
D3	O
(cholecalciferol	O
(vitamin	O
D3))	O
1,000	O
unit	O
oral	O
DAILY	O
Discharge	O
Medications:	O
1.	O
Acyclovir	O
400	O
mg	O
PO	O
Q8H	O
2.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
3.	O
FoLIC	O
Acid	O
0.8	O
mg	O
PO	O
DAILY	O
4.	O
Lorazepam	O
0.5-1	O
mg	O
PO	O
TID	O
PRN	O
anxiety	O
prior	O
to	O
IV	O
placement	O
5.	O
Mirtazapine	O
7.5	O
mg	O
PO	O
QHS	O
6.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
7.	O
Omeprazole	O
20	O
mg	O
PO	O
DAILY	O
8.	O
OxycoDONE	O
(Immediate	O
Release)	O
5	O
mg	O
PO	O
Q4H:PRN	O
pain	O
9.	O
Sulfameth/Trimethoprim	O
SS	O
1	O
TAB	O
PO	O
DAILY	O
10.	O
Vitamin	O
D3	O
(cholecalciferol	O
(vitamin	O
D3))	O
1,000	O
unit	O
oral	O
DAILY	O
11.	O
Lidocaine-Prilocaine	O
1	O
Appl	O
TP	O
ONCE	O
12.	O
OxyCODONE	O
SR	O
(OxyconTIN)	O
20	O
mg	O
PO	O
Q8H	O
RX	O
*oxycodone	O
[OxyContin]	O
20	O
mg	O
1	O
tablet(s)	O
by	O
mouth	O
Q8hrs	O
Disp	O
#*90	O
Tablet	O
Refills:*0	O
13.	O
Dexamethasone	O
20	O
mg	O
PO	O
DAILY	O
Duration:	O
1	O
Dose	O
Just	O
take	O
on	O
___	O
RX	O
*dexamethasone	O
4	O
mg	O
5	O
tablet(s)	O
by	O
mouth	O
Once	O
Disp	O
#*5	O
Tablet	O
Refills:*0	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
Anaplastic	O
Plasma	O
Cell	O
Myeloma,	O
s/p	O
Cytoxan	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_assistance
-	O
requires	O
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
Mrs.	O
___,	O
___	O
were	O
admitted	O
due	O
to	O
concern	O
that	O
your	O
myeloma	O
has	O
relapsed.	O
We	O
started	O
___	O
on	O
a	O
new	O
chemotherapy	O
to	O
help	O
treat	O
your	O
myeloma	O
in	O
hopes	O
that	O
your	O
hip	O
pain	O
will	O
also	O
improve.	O
We	O
did	O
an	O
MRI	O
of	O
your	O
Pelvis	O
and	O
the	O
study	O
showed	O
no	O
evidence	O
of	O
a	O
pathologic	O
fracture.	O
Overall,	O
___	O
tolerated	O
this	O
chemotherapy	O
well	O
and	O
will	O
be	O
discharged	O
today.	O
Please	O
take	O
dexamethasone	O
20	O
mg	O
on	O
___.	O
___	O
will	O
follow	O
up	O
with	O
your	O
outpatient	O
provider	O
as	O
listed	O
below.	O
In	O
addition	O
to	O
this,	O
___	O
also	O
have	O
appointments	O
with	O
Dr.	O
___	O
oncologist)	O
for	O
radiation	O
therapy.	O
Please	O
do	O
not	O
hesistate	O
to	O
contact	O
us	O
if	O
___	O
have	O
any	O
questions	O
or	O
concerns	O
about	O
your	O
care.	O
Sincerely,	O
Your	O
___	O
Team	O
Followup	O
Instructions:	O
___	O

